Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.
You may also be interested in...
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.